ST. LOUIS--(BUSINESS WIRE)--Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that Health Canada has approved the Company’s Abbreviated New Drug Submission (ANDS) for its Kit for the Preparation of Technetium Tc 99m Sestamibi Injection. Covidien’s generic product is fully substitutable for Cardiolite®, a myocardial perfusion imaging agent used for detecting coronary artery disease.
